- Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Ilie MD, Villa C, Cuny T, Cortet C, Assié G, Baussart B, Cancel M, Chanson P, Decoudier B, Deluche E, Di Stefano AL, Drui D, Gaillard S, Goichot B, Huillard O, Joncour A, Larrieu-Ciron D, Libe R, Nars G, Vasiljevic A, Raverot G.Eur J Endocrinol. 2022 Sep 1:EJE-22-0647. doi: 10.1530/EJE-22-0647.

 

- Clinical Biology of the Pituitary Adenoma. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.PMID: 35395078 

 

- Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators †.Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.PMID: 36018781

 

- Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Chanson P.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101711.doi:10.1016/ j.beem.

2022.101711.

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Raverot G, Ilie MD.

Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101712. doi: 10.1016/j.beem.2022.101712. Epub 2022 Oct 12.PMID: 36274025 Review.

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary AdenomasIlie MD, Vasiljevic A, Bertolino P, Raverot G. Endocr Rev. 2022 Oct 21:bnac024. doi: 10.1210/endrev/bnac024. Online ahead of print.PMID: 36269838

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM; ESE survey collaborators †. Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.PMID: 36018781

 

- Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. Zamanipoor Najafabadi AH, van der Meulen M, Priego Zurita AL, Faisal Ahmed S, van Furth WR, Charmandari E, Hiort O, Pereira AM, Dattani M, Vitali D, de Graaf JP, Biermasz NR; MTG6 Pituitary of Endo-ERN.Endocr Connect. 2022 Dec 13;12(1):e220349. doi: 10.1530/EC-22-0349. Print 2023 Jan 1.PMID: 36327151 

 

- Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm. Calvanese F, Jacquesson T, Manet R, Vasiljevic A, Lasolle H, Ducray F, Raverot G, Jouanneau E.Front Endocrinol (Lausanne). 2022 Jun 9;13:882381. doi: 10.3389/fendo.2022.882381. eCollection 2022.PMID: 35757402 Free PMC article. Review.

 

- Five-Year Changes in Weight and Diabetes Status After Bariatric Surgery for Craniopharyngioma-Related Hypothalamic Obesity: a Case-Control Study. Faucher P, Carette C, Jannot AS, Gatta-Cherifi B, Van Straaten A, Piquet MA, Raverot G, Alligier M, Batisse T, Ziegler O, Drui D, Bretault M, Farigon N, Slim K, Genser L, Poghosyan T, Vychnevskaia K, Blanchard C, Robert M, Gronnier C, Poitou C, Czernichow S.Obes Surg. 2022 Jul;32(7):2321-2331. doi: 10.1007/s11695-022-06079-9. Epub 2022 May 6.PMID: 35524022

 

- The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal? Cuny T, Buchfelder M, Dufour H, Grossman A, Gatta-Cherifi B, Jouanneau E, Raverot G, Vasiljevic A, Castinetti F.Cancers (Basel). 2022 Aug 7;14(15):3831. doi: 10.3390/cancers14153831.PMID: 35954494 Free PMC article. Review

 

- Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles? Rodier C, Courbière B, Fernandes S, Vermalle M, Florence B, Resseguier N, Brue T, Cuny T.Front Endocrinol (Lausanne). 2022 Feb 18;13:832361. doi: 10.3389/fendo.2022.832361. eCollection 2022.PMID: 35250884

 

- Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience.

Lasolle H, Teulade M, Lapras V, Vasiljevic A, Borson-Chazot F, Jouanneau E, Raverot G.Ann Endocrinol (Paris). 2022 Feb;83(1):1-8. doi: 10.1016/j.ando.2021.11.008.

 

- Prolactin immunoassay: does the high-dose hook effect still exist? Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G.Pituitary. 2022 Aug;25(4):653-657. doi: 10.1007/s11102-022-01246-8. Epub 2022 Jul 6.PMID: 35793045

 

- The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal? Cuny T, Buchfelder M, Dufour H, Grossman A, Gatta-Cherifi B, Jouanneau E, Raverot G, Vasiljevic A, Castinetti F.Cancers (Basel). 2022 Aug 7;14(15):3831. doi: 10.3390/cancers14153831.

 

- Current and Emerging Medical Therapies in Pituitary Tumors. Sahakian N, Castinetti F, Brue T, Cuny T.J Clin Med. 2022 Feb 12;11(4):955. doi: 10.3390/jcm11040955.

 

- Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Tritos NA, Fazeli PK, McCormack A, Mallea-Gil SM, Pineyro MM, Christ-Crain M, Frara S, Labadzhyan A, Ioachimescu AG, Shimon I, Takahashi Y, Gurnell M, Fleseriu M; “Pituitary Society Delphi Collaborative Group”.Pituitary. 2022 Feb;25(1):64-73. doi: 10.1007/s11102-021-01170-3.

 

- Intratumoural spatial distribution of S100B + folliculostellate cells is associated with proliferation and expression of FSH and ERα in gonadotroph tumours. Ilie MD, Vasiljevic A, Chanal M, Gadot N, Chinezu L, Jouanneau E, Hennino A, Raverot G, Bertolino P.Acta Neuropathol Commun. 2022 Feb 9;10(1):18. doi: 10.1186/s40478-022-01321-y.PMID: 35139928

 

- Clinical Biology of the Pituitary Adenoma. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY.Endocr Rev. 2022 Apr 8:bnac010. doi: 10.1210/endrev/bnac010. Online ahead of print.PMID: 35395078

 

- Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Guðmundsson K, Guevara-Aguirre J, Ho KKY, Horikawa R, Isidori AM, Jørgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo X, McCormack AI, Meacham L, Melmed S, Mostoufi Moab S, Müller HL, Neggers SJCMM, Aguiar Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G.Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52. doi: 10.1530/EJE-21-1186.

 

- Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Ilie MD, Vasiljevic A, Jouanneau E, Raverot G.Endocr Relat Cancer. 2022 May 27;29(7):415-426. doi: 10.1530/ERC-22-0037.PMID:35521777

 

- Health care expenditures among long-term survivors of pediatric solid tumors: Results from the French Childhood Cancer Survivor Study (FCCSS) and the French network of cancer registries (FRANCIM). Bejarano-Quisoboni D, Pelletier-Fleury N, Allodji RS, Lacour B, GrosClaude P; FRANCIM Group, Pacquement H, Doz F, Berchery D, Pluchart C, Bondiau PY, Nys J, Jackson A, Demoor-Goldschmidt C, Dumas A, Thomas-Teinturier C, Vu-Bezin G, Valteau-Couanet D, Haddy N, Fresneau B, de Vathaire F.PLoS One. 2022 May 26;17(5):e0267317. doi: 10.1371/journal.pone.0267317.

 

- Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. Kuhn E, Weinreich AA, Biermasz NR, Jorgensen JOL, Chanson P. Eur J Endocrinol. 2021 May 24;185(1):99-108. doi: 10.1530/EJE-21-0145. PMID: 33914699.

- The risks of medical treatment of prolactinoma. Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T.Ann Endocrinol (Paris). 2021 Feb;82(1):15-19. doi: 10.1016/j.ando.2020.12.008. Epub 2020 Dec 26. PMID: 33373604 Review.
 

- THE RISKS OF MEDICAL TREATMENT OF PROLACTINOMA.
Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T. Ann Endocrinol (Paris). 2020 Dec 26:S0003-4266(20)31318-4. doi: 10.1016/j.ando.2020.12.008. Online ahead of print.

- Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma.
Allard L, Albarel F, Bertherat J, Caron PJ, Cortet C, Courtillot C, Delemer B, Jublanc C, Maiter D, Nunes ML, Raverot G, Sarfati J, Salenave S, Corruble E, Choucha W, Chanson P.Eur J Endocrinol. 2020 Aug 1;183(2):221-231. doi: 10.1530/EJE-20-0125.PMID: 32583656.

- Women's perceptions of femininity after craniopharyngioma: a qualitative study.
Eydoux R, Castinetti F, Authier M, Vialle M, Albarel F, Brue T, Courbiere B. Clin Endocrinol (Oxf). 2020 Dec 9. doi: 10.1111/cen.14378. Online ahead of print.PMID: 33296092.

- Germinal defects of SDHx genes in patients with isolated pituitary adenoma.
Mougel G, Lagarde A, Albarel F, Essamet W, Luigi P, Mouly C, Vialon M, Cuny T, Castinetti F, Saveanu A, Brue T, Barlier A, Romanet P. Eur J Endocrinol. 2020 Oct;183(4):369-379. doi: 10.1530/EJE-20-0054.PMID: 32621582.

- Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma.
Illouz F, Chanson P, Sonnet E, Brue T, Ferriere A, Raffin Sanson ML, Vantyghem MC, Raverot G, Munier M, Rodien P, Briet C. Eur J Endocrinol. 2021 Jan;184(1):1-8. doi: 10.1530/EJE-20-0484.PMID: 33112257.

- Surgical indications for pituitary tumors during pregnancy: a literature review.
Graillon T, Cuny T, Castinetti F, Courbière B, Cousin M, Albarel F, Morange I, Bruder N, Brue T, Dufour H. Pituitary. 2020 Apr;23(2):189-199. doi: 10.1007/s11102-019-01004-3.PMID: 31691893 Review.

- Brief Communication Circulating tumor DNA is present in the most aggressive meningiomas.
Graillon T, Roche C, Basset N, Mougel G, Meyer M, Farah K, Boissonneau S, Fuentes S, Tabouret E, Campello C, Appay R, Figarella-Branger D, Chinot O, Dufour H, Romanet P, Barlier A. Neurooncol Adv. 2020 Jun 7;2(1):vdaa068. doi: 10.1093/noajnl/vdaa068. eCollection 2020 Jan-Dec.PMID: 32642718 Free PMC article. No abstract available.

- Parasellar Meningiomas. Graillon T, Regis J, Barlier A, Brue T, Dufour H, Buchfelder M. Neuroendocrinology. 2020;110(9-10):780-796. doi: 10.1159/000509090. Epub 2020 Jun 3.PMID: 32492684 Free article. Review.

- Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL. Clin Cancer Res. 2020 Feb 1;26(3):552-557. doi: 10.1158/1078-0432.CCR-19-2109. Epub 2020 Jan 22.PMID: 31969329 Clinical Trial.

- Ophthalmoplegic complications in transsphenoidal pituitary surgery.
Florea SM, Graillon T, Cuny T, Gras R, Brue T, Dufour H. J Neurosurg. 2019 Jul 26:1-9.

- PCOS and Hyperprolactinemia: what do we know in 2019?
Delcour C, Robin G, Young J, Dewailly D. Clin Med Insights Reprod Health. 2019 Sep 9.

- Prolactin - a pleiotropic factor in health and disease.
Bernard V, Young J, Binart N. Nat Rev Endocrinol. 2019 Jun;15(6):356-365. 

- Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma - commentary.
Raverot G, Vasiljevic A, Jouanneau E, Lasolle H. Eur J Endocrinol. 2019 Jun 1.

- Clinical management of difficult to treat macroprolactinomas.
Sahakian N, Castinetti F, Dufour H, Graillon T, Romanet P, Barlier A, Brue T, Cuny T. Expert Rev Endocrinol Metab. 2019 May;14(3):179-192.

- Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review.
Graillon T, Castinetti F, Chabert-Orsini V, Morange I, Cuny T, Albarel F, Brue T, Dufour H. Ann Endocrinol (Paris). 2019 Apr;80(2):122-127.

- Aggressive and Malignant Prolactinomas.
Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, Gahete MD; EYRC (ENEA Young Researcher Committee). Neuroendocrinology. 2019 Jan 24. [Epub ahead of print] Review.
 

- The Epidemiology, Diagnosis And Treatment Of Prolactinomas : The Old And The New  

Chanson P., Maiter D.
Best Pract Res Clin Endocrinol Metab 2019 Jul 10

 

- Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.

Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea ML, Naves LA, Rodien P, Rohmer V, Faucz FR, Caron P, Estour B, Lecomte P, Borson-Chazot F, Penfornis A, Yaneva M, Guitelman M, Castermans E, Verhaege C, Wémeau JL, Tabarin A, Fajardo Montañana C, Delemer B,  Kerlan V, Sadoul JL, Cortet Rudelli C, Archambeaud F, Zacharieva S, Theodoropoulou M, Brue T, Enjalbert A, Bours V, Pellegata NS, Beckers A.

Endocr Relat Cancer. 2012 May 3;19(3):233-41.             

 

 - Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. 

Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T.

Clin Endocrinol (Oxf). 2012Jun;76(6):769-75.             

 

- Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.

Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, Conte-Devolx B, Brue T, Castinetti F.

Ann Endocrinol (Paris). 2012 Jun;73(3):225-9.           

     

 - Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.

 Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A.

Eur J Endocrinol. 2012 Nov;167(5):651-62.- High prevalence of AIP gene mutations following focussed screening in young patients with sporadic pituitary macroadenomas.

Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo Montanana C, Hana V, Halaby G, Delemer B, Labarta Izmun I, Sonnet E, Ferrandez Longas A, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A.

Eur . J. Endocrinol. 2011; oct; 165(4):509-515.

 

- A conservative management is preferable in milder forms of pituitary tumor apoplexy.

Leyer C*, Castinetti F*, Morange I, Gueydan M, Oliver C, Conte-Devolx B, Dufour H, Brue T. (* co-1st auteurs)

J. Endocrinol. Invest. 2011 Jul-Aug;34(7):502-9

 

- Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.

Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-rea ML, Barlier A, Naves LA, Ebeling T, Harhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Maschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo Ap, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen §LA, Beckers A.

J. Clin. Endocrinol. Metab. 2010, no;95(11):E373-83.

 

- Prognostic factors in prolactin pituitary tumors: clinical, histological and molecular data from a serie of 94 patients with a long postoperative follow-up.

Raverot G., Wierinckx A., Dantony E., Auger C., Chapas G. , Villeneuve L., Brue T., Figarella-Branger D., Roy P., Jouanneau E., Jan M., Lachuer J., Trouillas J. And The Members Of Hypopronos

J. Clin. Endocrinol. Metab. 2010 Apr;95(4):1708-1716.

 

- Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Raverot G, Sturm N, De Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia Jg, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.

J. Clin. Endocrino. Metab. 2010 Oct;95(10):4592-9.

 

- Expression of Aryl Hydrocarbon Receptor (AHR) and Aryl hydrocarbon receptor Interacting Protein (AIP) in pituitary adenomas: pathological and clinical implications.

Jaffrain-Rea M.L., Angelini M., Gargano D., Tichomirowa M.A., Daly A.F., Vanbellinghen J.F., D’innocenzo E., Barlier A., Giangaspero F., Esposito V., Ventura L., Arcella A., Theodoropoulou M., Naves L.A., Fajardo C., Zacharieva S., Rohmer V., Brue T., Gulino A., Cantore G., Alesse E., Beckers A.

Endocrine Related Cancer, 2009;16(3):1029-1043.

 

 - ACROSTUDY: Status Update on 469 Patients

Thierry Brue on behalf of all ACROSTUDY Investigators

Horm Res 2009;71(suppl 1):34–38.

 

- Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.

Acunzo J., Thirion S., Roche C., Saveanu A., Gunz G., Germanetti A.L., Couderc B., Cohen R., Figarella-Branger D., Dufour H., Brue T., Enjalbert A., Barlier A.

Cancer Research, 2008;68(24):10163-70.

 

- Diagnosis and management of hyperprolactinemia: expert consensus - French Society
of Endocrinology.

Brue T, Delemer B; French Society of Endocrinology (SFE) work group on the consensus on hyperprolactinemia.
Ann. Endocrinol. (Paris). 2007;68(1):58-64.

 

- Prolactinoma Surgery.

Han M, Dufour H, Brue T, Jaquet P.

Ann. Endocrinol. (Paris). 2007;68(2-3):118-19.

 

- Etiological diagnosis of hyperprolactinemia.

Cortet-Rudelli C, Sapin R, Bonneville JF, Brue T.

Ann. Endocrinol. (Paris). 2007;68(2-3):98-105.

 

-  Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.

Saveanu A., Jaquet P., Brue T., Barlier A. 

Mol; Cell. Endocrinol. 2007 May; ():14;286(1-2):206-13.

 

 - Mutations in the Aryl Hydrocarbon Receptor Interacting Protein Gene are not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas.

Barlier A., Vanbellinghen J.F., Daly A.F., Sylvy M., Jaffrain-Rea M.L., Trouillas J., Tamagno G., Bours V., Brue T., Enjalbert A., Beckers A.

J. Clin. Endocrinol. Metab. 2007, may; 92(5):1952-55.

 

- Aryl Hydrocarbon Receptor Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families.

Daly A F., Vanbellinghen J-F, Khoo S-K, Jaffrain Rea M-L, Calender A, Naves L. A., Guitelman M. A., Murat A., Emy P., Gimenez-Roqueplo A-P, Tamburrano G., Raverot G., Barlier A ., De Herder W., Penfornis A., Ciccarelli E., Estour B., Lecomte P., Gatta B., Chabre O., Sabaté M.I ., Bertagna X., Garcia Basavilbaso N., Stalldecker G., Colao A., Ferolla P., Wémeau J.L., Caron C., Sadoul J.L., Oneto A., Archambaud F., Fajardo Montañana C., Cavagnini F., Hana V.,  Solano A., Delettieres D., Luccio-Camelo D. C., Basso A., Rohmer V., Brue T., Bours V., Teh B.T., Beckers A..

J. Clin. Endocrinol. Metab. 2007, may; 92(5):1891-96.

 

- Differential Regulation of Proopiomelanocortin and Pituitary-Restricted Transcription Factor (TPIT), a New Marker of Normal and Adenomatous Human Corticotrophs

Sophie Vallette-Kasic, Dominique Figarella-Branger, Michel Grino, Anne-Marie Pulichino, Henry Dufour, François Grisoli, Alain Enjalbert, Jacques Drouin, and Thierry Brue

J Clin Endocrinol Metab 2003 88: 3050-3056

 

- Diagnosis and management of hyperprolactinemia: expert consensus –

French Society of EndocrinologyT. Brue, B. Delemerb, the members of the French Society of Endocrinology (SFE)

Annales d’Endocrinologie 68 (2007) 58–64 

 

 - Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

 Steve Bilodeau,  Sophie Vallette-Kasic, Yves Gauthier , Dominique Figarella-Branger, Thierry Brue , France Berthelet , André Lacroix  ,Dalia Batista,  Constantine Stratakis , Jeanette Hanson,  Björn Meij, and Jacques Drouin

Genes & Dev. 2006 20: 2871-2886

 

- Guidelines of the Pituitary Society for the diagnosis and management of Prolactinomas

Casanueva F.F., Molitch M.E., Schlechte J.A., Abs R., Bonert V., Bronstein M., Brue T., Cappabianca P., Colao A.M., Fahlbusch R., Fideleff H., Hadani M., Kelly P., Kleinberg D., Laws E., Marek J., Scanlon M., Sobrinho L.G., Wass J.A., Giustina A.

Clin. Endocrinol. (Oxf) 2006, aug;65(2):265-73.

 

- Clinical characterization of familial isolated pituitary adenomas.

Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., Valdes-Socin H., Rohmer V., Tamburrano G., Borson-Chazot F., Estour B., Ciccarelli E., Brue T., Ferolla P., Emy P., Colao A., De Menis E., Lecomte P., Penfornis F., Delemer B., Bertherat J., Wemeau J.L., De Herdre W., Archambeaud F., Stevenaert A., Calender A., Murat A., Cavagnini F., Beckers A.

J. Clin. Endocrinol. Metab. 2006, sep;91(9):3316-3323.

 

- Diagnostic et prise en charge des hyperprolactinémies-- Consensus d’experts de la Société Française d’Endocrinologie (SFE)

Thierry Brue, Brigitte Delemer, J. Bertherat, J.F. Bonneville, F. Borson-Chazot, O. Chabre, P. Chanson, S. Christin-Maitre, B.  Claustrat, C. Cortet-Rudelli , H. Dufour, B. Estour, M. Jan, P. Jaquet, P.Kelly, G. Perrin, R. Sapin, P.Touraine, J. Trouillas, J. Young

Médecine Clinique endocrinologie & diabète • Hors-série • Septembre 2006